Biogen Inc. Files 8-K on Material Agreements and Obligations
Ticker: BIIB · Form: 8-K · Filed: 2024-08-14T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, financial-obligation, corporate-action
TL;DR
Biogen filed an 8-K on Aug 12th for material agreements & obligations - details to follow.
AI Summary
Biogen Inc. filed an 8-K on August 14, 2024, reporting on events that occurred on August 12, 2024. The filing indicates the entry into and termination of material definitive agreements, as well as the creation of direct financial obligations. Specific details regarding the nature of these agreements and obligations are not provided in this excerpt.
Why It Matters
This filing signals significant corporate actions by Biogen, potentially impacting its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates material definitive agreements and financial obligations, which could carry significant financial or operational risks for the company.
Key Players & Entities
- BIOGEN INC. (company) — Registrant
- 0000875045 (company) — Central Index Key
- 225 BINNEY STREET (company) — Business Address
- CAMBRIDGE (company) — Business City
- MA (company) — Business State
- 02142 (company) — Business Zip
- 7814642000 (company) — Business Phone
FAQ
What specific material definitive agreements did Biogen Inc. enter into?
The provided excerpt does not specify the details of the material definitive agreements entered into by Biogen Inc.
What are the terms of the terminated material definitive agreements?
The excerpt does not provide information on the terms of the terminated material definitive agreements.
What is the nature of the direct financial obligation created by Biogen Inc.?
The filing indicates the creation of a direct financial obligation, but the specific nature and amount are not detailed in this excerpt.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 12, 2024.
What is Biogen Inc.'s primary business as indicated by its SIC code?
Biogen Inc.'s Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 1,152 words · 5 min read · ~4 pages · Grade level 10.9 · Accepted 2024-08-14 16:30:57
Key Financial Figures
- $0.0005 — ange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Se
- $1.5 billion — "). The Credit Agreement provides for a $1.5 billion five-year unsecured, revolving credit f
- $25.0 million — the form of letters of credit of up to $25.0 million and $20.0 million in swing line loans.
- $20.0 million — rs of credit of up to $25.0 million and $20.0 million in swing line loans. Borrowings under
Filing Documents
- d867868d8k.htm (8-K) — 27KB
- d867868dex101.htm (EX-10.1) — 726KB
- g867868g0813084617349.jpg (GRAPHIC) — 2KB
- 0001193125-24-200660.txt ( ) — 1042KB
- biib-20240812.xsd (EX-101.SCH) — 3KB
- biib-20240812_lab.xml (EX-101.LAB) — 17KB
- biib-20240812_pre.xml (EX-101.PRE) — 11KB
- d867868d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. The exhibit listed below is furnished as part of this Current Report on Form 8-K. Exhibit No. Description Exhibit 10.1 Credit Agreement, dated as of August 12, 2024, among Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and the L/C issuer, and the other lenders party thereto 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 4 -
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biogen Inc. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: August 14, 2024 - 5 -